藥業股普遍捱沽 信達生物(01801.HK)和藥明康德(02359.HK)挫逾9%-10%
內地醫藥及生物疫苗板塊跌約1%,本港藥業股今天普遍捱沽,尤其是藥明康德(02359.HK)今早股價曾反彈至126.7元無以爲繼,掉頭失守20天及10天線(124.7元及125.8元),午後低見110.3元,現報111元,續挫10.5%,成交增至411萬股。旗下藥明生物(02269.HK)四連挫,最低見78.9元,現報79.05元,續挫7.6%,爲最傷藍籌,成交增至1,992萬股。藥明巨諾-B(02126.HK)股價連續第二天反覆創上市新低,今天高開報10.62元欠承接,掉頭低見10.1元,現報10.14元,續跌2.9%。
遭大和削價至48元的信達生物(01801.HK)四連跌,今早股價曾反彈3.3%至42.25元(受制20天線42.4元),掉頭向下,最低見36.9元,現報37.1元,急挫9.3%,成交增至1,183萬股。
復星醫藥(02196.HK)、威高股份(01066.HK)、康希諾生物(06185.HK)及治療痤瘡藥中國II期臨牀試驗完成首例患者給藥的開拓藥業(09939.HK)續跌近3%-6%,後者沽壓最大報9.4元,反覆續挫5.9%。
據《21世紀經濟報道》報道,第七批國家集中帶量採購工作已啓動。據業內流傳一份由國家組織藥品聯合採購辦公室發佈的《關於報送第七批國家組織藥品集中採購品種範圍相關採購數據的通知》顯示,第七批國採共涉及59個品種,208個品規。其中不乏奧美拉唑注射劑、美羅培南、美託洛爾等億元量級的大品種。該通知顯示,今日正式啓動報量,各省導入2021年曆史採購量數據供醫療機構參考,醫療機構須按要求填報相關藥品採購需求量,並於2月16日24:00前提交數據。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.